<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/55D85F5D-EB2A-4BE6-A76F-54B480468B1A"><gtr:id>55D85F5D-EB2A-4BE6-A76F-54B480468B1A</gtr:id><gtr:name>Department of Clinical Neurosciences</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/6878F160-3C35-4AC6-8D56-FBD6D6FB37B4"><gtr:id>6878F160-3C35-4AC6-8D56-FBD6D6FB37B4</gtr:id><gtr:name>Amgen Inc</gtr:name><gtr:address><gtr:line1>One Amgen Center Drive</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/76B9E34F-0CE7-44BC-A9AA-B08CFBDF4FD2"><gtr:id>76B9E34F-0CE7-44BC-A9AA-B08CFBDF4FD2</gtr:id><gtr:name>Society of British Neurological Surgeons</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/C1FFEA46-9B1E-4484-B889-23D42E20092E"><gtr:id>C1FFEA46-9B1E-4484-B889-23D42E20092E</gtr:id><gtr:name>International Neurotrauma Society (INTS)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/E76C7F07-63A8-4C65-918D-F4FE5A2E4F83"><gtr:id>E76C7F07-63A8-4C65-918D-F4FE5A2E4F83</gtr:id><gtr:name>European Brain Injury Consortium (EBIC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:department>Life Sciences</gtr:department><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/55D85F5D-EB2A-4BE6-A76F-54B480468B1A"><gtr:id>55D85F5D-EB2A-4BE6-A76F-54B480468B1A</gtr:id><gtr:name>Department of Clinical Neurosciences</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/6878F160-3C35-4AC6-8D56-FBD6D6FB37B4"><gtr:id>6878F160-3C35-4AC6-8D56-FBD6D6FB37B4</gtr:id><gtr:name>Amgen Inc</gtr:name><gtr:address><gtr:line1>One Amgen Center Drive</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/76B9E34F-0CE7-44BC-A9AA-B08CFBDF4FD2"><gtr:id>76B9E34F-0CE7-44BC-A9AA-B08CFBDF4FD2</gtr:id><gtr:name>Society of British Neurological Surgeons</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C1FFEA46-9B1E-4484-B889-23D42E20092E"><gtr:id>C1FFEA46-9B1E-4484-B889-23D42E20092E</gtr:id><gtr:name>International Neurotrauma Society (INTS)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/E76C7F07-63A8-4C65-918D-F4FE5A2E4F83"><gtr:id>E76C7F07-63A8-4C65-918D-F4FE5A2E4F83</gtr:id><gtr:name>European Brain Injury Consortium (EBIC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/73EF20E7-5752-4BD1-9E7C-31F7A4D89D44"><gtr:id>73EF20E7-5752-4BD1-9E7C-31F7A4D89D44</gtr:id><gtr:firstName>Andy</gtr:firstName><gtr:surname>Vail</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/DC247267-DA2E-47CD-838A-348F17241C68"><gtr:id>DC247267-DA2E-47CD-838A-348F17241C68</gtr:id><gtr:firstName>Nancy</gtr:firstName><gtr:otherNames>Jane</gtr:otherNames><gtr:surname>Rothwell</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/ABCBB528-7405-4626-86A0-B43F95164F37"><gtr:id>ABCBB528-7405-4626-86A0-B43F95164F37</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Hutchinson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/27A3C75A-277A-428C-B8D9-C28D514C70DF"><gtr:id>27A3C75A-277A-428C-B8D9-C28D514C70DF</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:surname>Hopkins</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/8F8F79CB-0439-4A6F-A5F7-77FB440B27CD"><gtr:id>8F8F79CB-0439-4A6F-A5F7-77FB440B27CD</gtr:id><gtr:firstName>Rachel</gtr:firstName><gtr:surname>Georgiou</gtr:surname><gtr:orcidId>0000-0002-0920-0602</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/079C2DD0-6648-4B72-ACF3-C7A7EACEB9BC"><gtr:id>079C2DD0-6648-4B72-ACF3-C7A7EACEB9BC</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:otherNames>Thomas</gtr:otherNames><gtr:surname>King</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/9C48B744-E412-4B94-BB51-EFE0AEE37BA0"><gtr:id>9C48B744-E412-4B94-BB51-EFE0AEE37BA0</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:surname>Kirkpatrick</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/9A5F8319-A8D3-437B-9AE4-B00F04652603"><gtr:id>9A5F8319-A8D3-437B-9AE4-B00F04652603</gtr:id><gtr:firstName>Pippa</gtr:firstName><gtr:otherNames>Jane</gtr:otherNames><gtr:surname>Tyrrell</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0502030"><gtr:id>4D3FE26D-BCA8-4881-A74F-F475C683ACA6</gtr:id><gtr:title>Translating experimental stroke therapy to patients: determination of optimal dosing and biological efficacy of IL-1ra</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0502030</gtr:grantReference><gtr:abstractText>Stroke is the third biggest killer world wide and the most common cause of adult disability in the UK. Deaths caused by stroke will nearly double in the next decade. Despite this, there are few treatments.

Many studies of potential new treatments have failed, some because it was not fully understood how the treatment worked and how best to give it.

A stroke occurs when the blood supply to the brain is disrupted. This causes inflammation in the brain. We have been working on a possible new treatment for stroke, called IL-1ra. IL-1ra is a copy of a naturally occurring chemical that blocks inflammation and is already used in diseases like rheumatoid arthritis. It would be given soon after a stroke and would work by protecting brain cells from damage. 

We have given IL-1ra to a small number of stroke patients to check that is safe. We are planning to move on to the next stage of developing the treatment (Phase III study) to see how effective it is. Before we do this we want to be sure we are giving the right dose, in the best way.

We have completed a study which looked at how the IL-1ra gets into brain from the blood stream. This study was done in patients with subarachnoid haemorrhage (SAH) who had a tube draining fluid (cerebrospinal fluid, CSF) from around the brain to relieve pressure. We collected samples of the CSF to measure IL-1ra and found that it can take up to four hours to reach protective levels. After a stroke we need to get enough IL-1ra into the brain as quickly as possible to protect it from damage. 

In the proposed studies we want to:
1. Give different amounts of IL-1ra to find the dose that gets enough IL-1ra into the CSF quickly. 
2. Measure the effect of IL-1ra on inflammation in the brain of patients with SAH, using the dose found in study 1. This will be done by measuring markers of inflammation in samples of CSF and from within the brain (using a technique called microdialysis).

3. Give IL-1ra to patients with stroke to check whether it is having the same effect as in patients with SAH. 

This will ensure that we design the safest and most effective clinical trial that we can.</gtr:abstractText><gtr:technicalSummary>This proposal addresses one of the greatest unmet clinical needs, cerebral ischaemia, and is therefore relevant to stroke, haemorrhage, brain injury, vascular dementia and birth hypoxia.

There is now extensive evidence that the cytokine interleukin-1 (IL-1) is a key mediator of experimentally-induced cerebral ischaemia. The endogenous IL-1 receptor antagonist (IL-1ra) markedly reduces diverse forms of ischaemic, traumatic and excitotoxic brain injury in rodents and is effective when given some hours after the injury. As a result of these findings we have undertaken a small Phase II study of IL-1ra in acute stroke. IL-1ra was safe, markedly inhibited markers of peripheral inflammation and showed potentially promising effects on outcome. We have demonstrated that iv treatment with IL-1ra in SAH patients results in CSF levels that are at least as high as those found in rodents when neuroprotection is seen.

This proposal addresses two questions that are critical before a full Phase III efficacy trial of IL-ra is undertaken in stroke and/or SAH:

What is the optimal dosing regime to achieve the most rapid levels of IL-1ra in the CNS?
Does IL-1ra inhibit CNS inflammation? This will provide important proof of principle for more extensive studies.

We will undertake most studies on SAH patients for pragmatic reasons.
1. We will compare CSF levels of IL-1ra administered iv in different doses to SAH patients.
2. We will study inflammatory markers in CSF, in brain tissue (by microdialysis) and in blood in SAH patients given IL-1ra (dose determined by 1) or placebo.
3. We will repeat study 2 in a small number of stroke patients.

Given the successful studies we have undertaken to date and the combined expertise of the applicants and collaborators, we believe that the studies proposed are highly feasible and will determine whether a full Phase III efficacy study is justified and how such a study might best be designed.</gtr:technicalSummary><gtr:fund><gtr:end>2010-12-27</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-12-28</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>520381</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Engineering</gtr:department><gtr:description>Engineering - finite element analysis of decompressive craniectomy</gtr:description><gtr:id>88B5746F-3F60-44D5-9C65-3D77F83694D7</gtr:id><gtr:impact>Publications</gtr:impact><gtr:partnerContribution>Finite element analysis of decompressive craniectomy</gtr:partnerContribution><gtr:piContribution>Increasing the understanding of the clinical consequences of brain deformation after craniectomy</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Department of Clinical Neurosciences</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:department>Division of Neurosurgery</gtr:department><gtr:description>13C-labelled microdialysis</gtr:description><gtr:id>6C5DB8A0-2C9A-4DF1-86E8-6CC4D9FFAFA8</gtr:id><gtr:impact>Publication: Gallagher CN, Carpenter KL, Grice P, Howe DJ, Mason A, Timofeev I, Menon DK, Kirkpatrick PJ, Pickard JD, Sutherland GR, Hutchinson PJ. The human brain utilizes lactate via the tricarboxylic acid cycle: a 13C-labelled microdialysis and high-resolution nuclear magnetic resonance study. Brain. 2009 Oct;132(Pt 10):2839-2849. PubMed PMID: 19700417.</gtr:impact><gtr:partnerContribution>Our collaborator has visited us in Cambridge on a Visiting Fellowship (awarded by the Canadian Institute of Health Research). The collaboration is ongoing and our collaborator is a Co-investigator on a current MRC Research Grant (PI: Peter Hutchinson, G1002277 ID 98489).</gtr:partnerContribution><gtr:piContribution>13C labelling studies of brain metabolism using microdialysis in traumatic brain injury patients.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Society of British Neurological Surgeons</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>British Neurosurgical Trainee Research Collaborative</gtr:description><gtr:id>E6C723B8-9876-4A27-931C-FCECE80FECFD</gtr:id><gtr:impact>PMID: 22583319</gtr:impact><gtr:partnerContribution>The SBNS has very generously supported this initiative since its inception.</gtr:partnerContribution><gtr:piContribution>AK and PH led the efforts to establish the British Neurosurgical Trainee Research Collaborative. The BNTRC is a research network for trainees which will aim to develop, run and support neurosurgical trials.</gtr:piContribution><gtr:sector>Learned Society</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>International Neurotrauma Society (INTS)</gtr:collaboratingOrganisation><gtr:country>Hungary, Republic of</gtr:country><gtr:description>International Multicentre Randomised Trial</gtr:description><gtr:id>4A750592-27E6-4841-B4B0-79BED7752AED</gtr:id><gtr:impact>Recruitment of 280 patients from 43 centres in 17 countries</gtr:impact><gtr:partnerContribution>Patient recruitment</gtr:partnerContribution><gtr:piContribution>Study set-up, patient recruitment and data collection</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Amgen Inc</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Provision of Amgen IL-1RA for clinical studies</gtr:description><gtr:id>FAD78A27-FD3C-4603-919D-E3B35EDEA4B3</gtr:id><gtr:impact>Pharmacokinetic study identified optimal dosing regime of IL-1RA in SAH patients to take forward to test efficacy in further trials. Phase II randomised controlled double blind trial (IL-1RA vs placebo) now completed in SAH patients (analysis in progress).</gtr:impact><gtr:partnerContribution>Provision of IL-1RA for clinical studies</gtr:partnerContribution><gtr:piContribution>Carried out pharmacokinetic study to identify optimal dosing regime of IL-1RA in SAH patients.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Society of British Neurological Surgeons</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>International Multicentre Randomised Trial</gtr:description><gtr:id>E97EC6AE-08EA-4D0D-8487-4C06BE381A1D</gtr:id><gtr:impact>Recruitment of 280 patients from 43 centres in 17 countries</gtr:impact><gtr:partnerContribution>Patient recruitment</gtr:partnerContribution><gtr:piContribution>Study set-up, patient recruitment and data collection</gtr:piContribution><gtr:sector>Learned Society</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Society of British Neurological Surgeons</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>British Neurotrauma Group</gtr:description><gtr:id>A0871266-08FC-4C78-AAE2-8B03D1C5C4F3</gtr:id><gtr:impact>The first academic meeting of the group took place in 2010 (October). The meeting was attended by neurosurgeons, neurorehabilitation consultants, endocrinologists, neurologists and specialist nurses.</gtr:impact><gtr:partnerContribution>Increasing understanding of the issues surrounding decompressive craniectomy in head injury</gtr:partnerContribution><gtr:piContribution>Initiative to set up a special-interest group within the Society of British Neurological Surgeons</gtr:piContribution><gtr:sector>Learned Society</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Brain Injury Consortium (EBIC)</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:description>International Multicentre Randomised Trial</gtr:description><gtr:id>6ABECFCB-2101-4F6B-BF97-533BFA469DEB</gtr:id><gtr:impact>Recruitment of 280 patients from 43 centres in 17 countries</gtr:impact><gtr:partnerContribution>Patient recruitment</gtr:partnerContribution><gtr:piContribution>Study set-up, patient recruitment and data collection</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Numerous scientific, public and policy talks - too many to detail</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>8F55BB38-F76A-4082-A9C0-9E0142F076C8</gtr:id><gtr:impact>Numerous scientific, public and policy talks - too many to detail.

Significant press coverage</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Keynote lecture to Schools Science Conference 2011</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>A10F832F-9307-407E-9D17-94C283C49198</gtr:id><gtr:impact>Talk followed by Q&amp;amp;A session. Title: &amp;quot;A stroke of bad luck - new discoveries in the treatment of brain disease&amp;quot;. Session: Science is the Future.
Venue : Royal College of Pathologists, London
Audience : 50 secondary year students from years 10-13 and their teachers

No specific impact known.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Frontiers of Science talk, Uni of Manchester</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>AA6E010B-B55A-452D-B173-5D1689CB3288</gtr:id><gtr:impact>Frontiers of Science talk delivered to ~150 undergraduate students from 1st year to 3rd year, followed by questions and discussion. 
Title: &amp;quot;Flaming brains - new discoveries about brain disease&amp;quot;


No specific impact known.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Annual STARS lecture, Manchester</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>77815BA8-B707-49D4-8397-5D6592D8AD7D</gtr:id><gtr:impact>Annual STARS lecture to ~200 local sixth form and college students.
Title: 'A stroke of bad luck: Understanding brain disease' (targeted at A level Biology).

Not known.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to Brain and Spinal Injury Charity (BASIC)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>25AD6FAC-EF91-4C43-932F-B50E2FC8BDE6</gtr:id><gtr:impact>50 members of the public and previous service users (patients and carers) received feedback from previous research studies, update on current research and details of further research plans.

All attendees have and wish to continue to contribute to the development of patient information sheets for clinical studies, which is invaluable in attaining ethical approval for clinical research studies.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Give approx. 10-12 public and schools lectures each year (too numerous to detail)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>674DEB77-551B-4C8C-8D88-B3B3745C17D6</gtr:id><gtr:impact>Give approx. 10-12 public and schools lectures each year (too numerous to detail)

Not possible to detail specific impacts - aim to increase interest in science, particularly in underprivileged areas. Often receive requests from school students wishing to do work experience in the lab, following a talk at their school (all of whom we aim to accommodate wherever possible).</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>All types and numerous locations; numerous examples</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>2DC0E3E7-3F84-43AF-94AF-03D418892D67</gtr:id><gtr:impact>Numerous scientific, public and policy talks - too many to detail.

Significant press coverage</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006,2007,2008,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Event for stroke patients and carers, Nov. 2010</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>DCB32A1C-3429-4981-9BA7-C5C8F2633208</gtr:id><gtr:impact>10 stroke survivors/carers attended an event called &amp;quot;Stroke research - from test tube to treatment&amp;quot;, which comprised talks from 3 researchers, spanning preclinical to clinical studies, and interacted with post-docs and students over various displays and refreshments. The feedback from attendees was mostly very positive and all but one expressed an interest in attending future events. The constructive feedback has made us re-evaluate what we want to achieve from such events and will inform future events.

We are re-evaluating the aims of such events and are planning further, larger events, taking into account the feedback received from this meeting. Specifically, we will be involved in a large event for World Stroke Day 2011, with our clinical colleagues.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>World Stroke Day 2011</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>222966E0-B87F-4348-B744-08F2848EC54A</gtr:id><gtr:impact>World Stroke Day event in Oct. 2011 organised by our clinical colleagues. The clinical investigator Dr Tyrrell presented the results of the clinical study funded by this grant. The audience comprised ~180 stroke patients and their carers, healthcare professionals and associated charities/organisations.

Not known.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lecture at the University of Birmingham</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>7692B4E4-B95F-42FF-B05C-D1C79CC321EB</gtr:id><gtr:impact>Talk title: &amp;quot;A stroke of bad luck: mechanisms and treatments for brain disease&amp;quot;. For ~200 Uni staff and students. Followed by questions and discussion.

No specific impact known.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>600000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Developmental Clinical Studies</gtr:description><gtr:end>2014-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G1001252</gtr:fundingRef><gtr:id>40FFAC3A-6DA8-40EE-9149-A881FA49A651</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>70000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Lectureship in Neurosurgery (University of Manchester and part MRC DCS grant)</gtr:description><gtr:fundingOrg>University of Manchester</gtr:fundingOrg><gtr:id>4FF3015B-CF8D-46B1-B492-D2DD54658C42</gtr:id><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>640000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Models of Disease Grant</gtr:description><gtr:end>2012-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G0801040</gtr:fundingRef><gtr:id>3BF8B835-D0F9-4068-9037-14C2BCB728C6</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-12-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Update to Trust EVD protocol</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>D0E492D9-DD6D-4793-BE83-E79085516FFA</gtr:id><gtr:impact>During the course of the PK study it was found that infection rates for SAH patients with external ventricular drains (EVDs) inserted was lower than the clinical average. This led to our researchers updating the EVD protocol for the local NHS Trust. Once approved by The Clinical Effectiveness Committee it will allow senior nurses as well as medics to sample from EVDs and standardize practice across Neuroscience. 
Nov. 2010: This has now been approved and research staff are responsible for training of clinical staff. Furthermore, nursing staff are now working to this protocol and have developed a care pathway for patients with EVDs. A re-audit of infection rates in patients with EVDs is planned for 2011. 
Nov. 2011: now published - see publications.
Further work is ongoing on CNS infection and relationship with predictive value of interleukin-6.</gtr:impact><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Neurosurgical Representative on the current NICE Committee revising the NICE guidelines for the early management of head injury in adults and children (due to be published published in 2013/4)</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4169C3C3-CE53-431B-9671-E0167540A93F</gtr:id><gtr:impact>Head injury guidelines</gtr:impact><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A07F9914-E433-4427-86FD-C0008F8A69ED"><gtr:id>A07F9914-E433-4427-86FD-C0008F8A69ED</gtr:id><gtr:title>The effect of intravenous interleukin-1 receptor antagonist on inflammatory mediators in cerebrospinal fluid after subarachnoid haemorrhage: a phase II randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Journal of neuroinflammation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ced39d1f99179e5ffe5edc968b042a67"><gtr:id>ced39d1f99179e5ffe5edc968b042a67</gtr:id><gtr:otherNames>Singh N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1742-2094</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/932675C3-02C9-47A6-AF6E-B182A0450561"><gtr:id>932675C3-02C9-47A6-AF6E-B182A0450561</gtr:id><gtr:title>Overcoming matrix matching problems in multiplex cytokine assays.</gtr:title><gtr:parentPublicationTitle>Journal of immunological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1c4d2e9a979098160c8703c32ebc0f08"><gtr:id>1c4d2e9a979098160c8703c32ebc0f08</gtr:id><gtr:otherNames>Hoadley ME</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1759</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4B87039D-FC8A-4ECF-8095-0446D2A9E4FF"><gtr:id>4B87039D-FC8A-4ECF-8095-0446D2A9E4FF</gtr:id><gtr:title>Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study.</gtr:title><gtr:parentPublicationTitle>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b0c38f830bd162cdd239e0c279b9e952"><gtr:id>b0c38f830bd162cdd239e0c279b9e952</gtr:id><gtr:otherNames>Galea J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0271-678X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AF02217A-83D5-479B-9621-68E3F4A23ACE"><gtr:id>AF02217A-83D5-479B-9621-68E3F4A23ACE</gtr:id><gtr:title>External ventricular drain infection: improved technique can reduce infection rates.</gtr:title><gtr:parentPublicationTitle>British journal of neurosurgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/df8805220164d455b58c3ebca1222813"><gtr:id>df8805220164d455b58c3ebca1222813</gtr:id><gtr:otherNames>Kitchen WJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0268-8697</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BD32C7FA-EE36-4A92-A5E3-6C83E7460083"><gtr:id>BD32C7FA-EE36-4A92-A5E3-6C83E7460083</gtr:id><gtr:title>Reconstituting National Institute for Biological Standards and Control (NIBSC) chemokines.</gtr:title><gtr:parentPublicationTitle>Cytokine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1c4d2e9a979098160c8703c32ebc0f08"><gtr:id>1c4d2e9a979098160c8703c32ebc0f08</gtr:id><gtr:otherNames>Hoadley ME</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1043-4666</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D624347F-0400-4C79-912A-217248E39CCB"><gtr:id>D624347F-0400-4C79-912A-217248E39CCB</gtr:id><gtr:title>Pitfalls in microdialysis methodology: an in vitro analysis of temperature, pressure and catheter use.</gtr:title><gtr:parentPublicationTitle>Physiological measurement</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c51e22fb235ead1dc290f09c51bec8e2"><gtr:id>c51e22fb235ead1dc290f09c51bec8e2</gtr:id><gtr:otherNames>Galea JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0967-3334</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0502030</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>A77DAE3A-499B-4F46-971D-6C82F51F9C2E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Stroke</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>